MedTrace Logo

Chloroprocaine Spinal for Outpatient Knee Surgery

NCT03365752 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-04-20

Study results available
· View outcomes & findings →

Summary

Outpatient knee surgeries with duration of less than one hour pose a challenge to the use of spinal anesthesia given that traditional agents remain in effect for 2-3 hours, thus creating a mismatch between length of surgery and anesthetic resolution. The investigators hypothesize that the use of chloroprocaine can combine the benefits of a short spinal anesthetic while avoiding the side effects of a general anesthetic, thus promoting earlier discharge.

Conditions

  • Knee Arthroscopy

Interventions

DRUG

Chloroprocaine

A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed

DRUG

Mepivacaine

A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed

DRUG

General Anesthetics

General anesthetics will be administered intravenously

Sponsors & Collaborators

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • David Kim · Hospital for Special Surgery, New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-24
Primary Completion
2021-02-04
Completion
2021-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03365752 on ClinicalTrials.gov